Repligen (RGEN)
Health Care · Bioprocessing technologies and equipment
Repligen makes bioprocessing technologies and systems that help biopharmaceutical companies and CDMOs manufacture biological drugs more efficiently and at scale.
What Repligen does
Repligen is a global life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacturing of biological drugs, including monoclonal antibodies (mAbs), recombinant proteins, RNA-based therapeutics, vaccines, and cell and gene therapies. The company sells products, equipment, and consumables to large biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and other life sciences integrators. Their offerings address critical customer needs around production cost reduction, capacity expansion, quality improvement, and time-to-market acceleration. The company has expanded its portfolio through acquisitions, including the 2025 acquisition of 908 Devices' process analytical technology (PAT) portfolio.
Themes: []
Fundamentals
- Price$143.94 as of 2026-07-09 close
- Market cap$8.0B as of 2026-07-10
- 1-year return+10.9% as of 2026-07-09 close
- P/E156.52 as of 2026-07-10
- Net margin+6.7% as of 2026-07-10
- Gross margin+53.1% as of 2026-07-10
- ROE+2.5% as of 2026-07-10
- Debt / equity0.26 as of 2026-07-10
- Revenue growth (YoY)+18.2% as of 2026-07-10
- Revenue CAGR (3y)+30.5% SEC XBRL
- Beta1.03 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.